Sunday, 16 August 2026European Markets
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
AI Platforms Move to Shore Up Trust as Leadership Shifts and AI-Adjacent Markets Wobble
Major AI and media platforms are converging on trust and accountability measures — Anthropic's Claude adding watermarks, Spotify labeling AI artists — just as OpenAI loses special-projects lead Brad Lightcap and Meta's Zuckerberg publishes a defensive manifesto on AI's societal role. In parallel, AI-adjacent financial dynamics are surfacing real stress: Wall Street firms are paying for privileged early access to Trump's Truth Social posts for trading edge, while Trump Media itself reports a $238M loss driven by falling crypto holdings, highlighting how information asymmetry and speculative digital assets are becoming entangled with AI-era platforms.
Our read on the data ›
Signals we're tracking
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patterns we're watching ›
Where sources disagree
JPMorgan Chase & Co.
Both facts report JPMorgan Chase & Co.'s revenue for the same fiscal period (FY 2025) with the same observation date (2025-12-31), but with different values: $182.447 billion vs. $185 billion. The ~1.4% difference ($2.553 billion) is too large to be explained by rounding alone and represents conflicting data for the identical time period.
We flag conflicts openly ›
Recently verified
Checked against the original source
4,809
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,809 facts checked against source5,205 source documents archived
Work with this data → vianewsagency.com

EUROFINS SCIENT. And VETOQUINOL Have A High Dividend Yield And Return On Equity In The Healthcare Sector.

Loading stream...

(vianews) - eurofins scient. (erf.pa) is among this list of stock assets with the highest dividend rate and return on equity on the healthcare sector.

financial asset price forward dividend yield return on equity
eurofins scient. (erf.pa) €59.08 1.92% 6.16%
vetoquinol (veto.pa) €99.50 0.88% 10.98%

several euronext companies pay out dividends to its shareholders. the dividend yield is a dividend to price ratio showing how much a company pays out in dividends each year.

1. eurofins scient. (erf.pa)

1.92% forward dividend yield and 6.16% return on equity

eurofins scientific se, together with its subsidiaries, provides various analytical testing and laboratory services worldwide. the company offers a portfolio of various analytical methods and tests to evaluate the safety, identity, composition, authenticity, origin, traceability, and purity of various products. it provides services such as agroscience, including biological assessment, consumer and human, and environmental safety, product chemistry, regulatory consultancy, and seed services; agro testing; assurance, such as product inspection, auditing, certification, training and consultation of food, consumer products, healthcare and cosmetics, and food supplements; biopharma, and clinical diagnostics. in addition, the company offers consumer product testing, which include sustainability, expert services and regulatory, consumer research and sensory evaluation, audits, testing, certifications and approvals, inspections, and training courses for various industries; cosmetics and personal care; environment testing, including water, air, soil, waste, and other products testing; and food and feed testing that include allergen, gmo, grain, meat, nano material, pesticides, and residual dna testing. further, it offers audit and certification, training and consulting; food irradiation and labelling, heavy metals, carbohydrates, radioactivity, nutritional analysis, microbiolody, and testing for persistent organic pollutants, veterinary drug residue, dioxins and organic contaminants, pesticides, mycotoxins, and vitamins, as well as analyses for genetic modifications. additionally, the company provides forensic, genomic, maritime, materials and engineering, reach, and other services. the company was founded in 1987 and is headquartered in luxembourg city, luxembourg.

earnings per share

as for profitability, eurofins scient. has a trailing twelve months eps of €1.57.

pe ratio

eurofins scient. has a trailing twelve months price to earnings ratio of 37.63. meaning, the purchaser of the share is investing €37.63 for every euro of annual earnings.

return on equity

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 6.16%.

more news about eurofins scient..

2. vetoquinol (veto.pa)

0.88% forward dividend yield and 10.98% return on equity

vetoquinol sa, a veterinary pharmaceutical company, designs, develops, and sells veterinary drugs and non-medicinal products in europe, the americas, and the asia pacific region. it provides products in the areas of mobility, pain, and inflammation; dermatology, hygiene, and care; anti-parasite; udder health; infectious diseases; reproduction; behavior management; internal medicine; and cardiology-nephrology for cattle, sheep, pigs, poultry, dogs, cats, and horses. the company was founded in 1933 and is headquartered in lure, france. vetoquinol sa is a subsidiary of soparfin sca.

earnings per share

as for profitability, vetoquinol has a trailing twelve months eps of €4.97.

pe ratio

vetoquinol has a trailing twelve months price to earnings ratio of 20.02. meaning, the purchaser of the share is investing €20.02 for every euro of annual earnings.

return on equity

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 10.98%.

more news about vetoquinol.